CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21.
The Citizens Life Sciences Conference
Date: Wednesday, May 7, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:00 p.m. – 3:25 p.m. ET
Location: New York, NY
The RBC 2025 Global Healthcare Conference
Date: Wednesday, May 21, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:35 p.m. – 4:00 p.m. ET
Location: New York, NY
The live webcast for each presentation can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND submission anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
This email address is being protected from spambots. You need JavaScript enabled to view it.
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$12.00 |
| Daily Change: | -0.51 -4.08 |
| Daily Volume: | 131,547 |
| Market Cap: | US$401.040M |
May 12, 2025 April 07, 2025 March 17, 2025 March 05, 2025 March 03, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
